Page last updated: 2024-08-07 23:16:46
Replicase polyprotein 1ab
[no definition available]
Synonyms
pp1ab;
ORF1ab polyprotein
Research
Bioassay Publications (21)
| Timeframe | Studies on this Protein(%) | All Drugs % |
|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 9 (42.86) | 29.6817 |
| 2010's | 7 (33.33) | 24.3611 |
| 2020's | 5 (23.81) | 2.80 |
Compounds (178)
Drugs with Inhibition Measurements
| Drug | Taxonomy | Measurement | Average (mM) | Bioassay(s) | Publication(s) |
|---|
| phloroglucinol | Severe acute respiratory syndrome-related coronavirus | IC50 | 200.0000 | 1 | 1 |
| taxifolin | Severe acute respiratory syndrome-related coronavirus | IC50 | 73.0000 | 1 | 1 |
| catechin | Severe acute respiratory syndrome-related coronavirus | IC50 | 100.0000 | 1 | 1 |
| 5,7-Dihydroxy-2-(3,4,5-trihydroxyphenyl)-3,4-dihydro-2H-chromen-3-yl 3,4,5-trihydroxybenzoate | Severe acute respiratory syndrome-related coronavirus | IC50 | 100.0000 | 1 | 1 |
| theophylline | Severe acute respiratory syndrome-related coronavirus | IC50 | 100.0000 | 1 | 1 |
| bronopol | Severe acute respiratory syndrome-related coronavirus | IC50 | 4.4000 | 1 | 1 |
| bronopol | Severe acute respiratory syndrome-related coronavirus | Ki | 2.5000 | 1 | 1 |
| caffeine | Severe acute respiratory syndrome-related coronavirus | IC50 | 100.0000 | 1 | 1 |
| N-[4-methyl-1-oxo-1-(1-oxohexan-2-ylamino)pentan-2-yl]carbamic acid (phenylmethyl) ester | Severe acute respiratory syndrome-related coronavirus | IC50 | 10.6900 | 1 | 1 |
| carmofur | Severe acute respiratory syndrome-related coronavirus | IC50 | 1.8200 | 2 | 2 |
| chloroquine | Severe acute respiratory syndrome-related coronavirus | IC50 | 5.4700 | 1 | 1 |
| chlorpromazine | Severe acute respiratory syndrome-related coronavirus | IC50 | 11.2400 | 1 | 2 |
| disulfiram | Severe acute respiratory syndrome-related coronavirus | IC50 | 9.3500 | 2 | 2 |
| disulfiram | Severe acute respiratory syndrome-related coronavirus | Ki | 3.7100 | 1 | 1 |
| ebselen | Severe acute respiratory syndrome-related coronavirus | IC50 | 0.6200 | 2 | 3 |
| emodin | Severe acute respiratory syndrome-related coronavirus | IC50 | 10.0000 | 1 | 1 |
| ethacrynic acid | Severe acute respiratory syndrome-related coronavirus | Ki | 375.0000 | 1 | 1 |
| fluphenazine | Severe acute respiratory syndrome-related coronavirus | IC50 | 11.8000 | 1 | 2 |
| hexachlorophene | Severe acute respiratory syndrome-related coronavirus | IC50 | 17.6100 | 1 | 2 |
| hydroxychloroquine | Severe acute respiratory syndrome-related coronavirus | IC50 | 3,584.0000 | 1 | 1 |
| beta-lapachone | Severe acute respiratory syndrome-related coronavirus | IC50 | 13.3300 | 1 | 1 |
| vitamin k 3 | Severe acute respiratory syndrome-related coronavirus | IC50 | 7.9600 | 1 | 1 |
| niclosamide | Severe acute respiratory syndrome-related coronavirus | IC50 | 46.0000 | 5 | 5 |
| promethazine | Severe acute respiratory syndrome-related coronavirus | IC50 | 13.6450 | 1 | 2 |
| protoporphyrin ix | Severe acute respiratory syndrome-related coronavirus | IC50 | 23.0000 | 1 | 1 |
| 3-[(3,5-dibromo-4-hydroxyphenyl)methylidene]-5-iodo-1H-indol-2-one | Severe acute respiratory syndrome-related coronavirus | IC50 | 21.5200 | 1 | 1 |
| alkannin | Severe acute respiratory syndrome-related coronavirus | IC50 | 15.7500 | 1 | 1 |
| triclosan | Severe acute respiratory syndrome-related coronavirus | IC50 | 75.0000 | 1 | 1 |
| pyromellitic acid | Severe acute respiratory syndrome-related coronavirus | Ki | 0.7000 | 1 | 1 |
| chloranil | Severe acute respiratory syndrome-related coronavirus | IC50 | 4.1000 | 1 | 1 |
| plumbagin | Severe acute respiratory syndrome-related coronavirus | IC50 | 17.1000 | 1 | 1 |
| aloe emodin | Severe acute respiratory syndrome-related coronavirus | IC50 | 132.0000 | 1 | 1 |
| dithiol | Severe acute respiratory syndrome-related coronavirus | Ki | 1.4000 | 1 | 1 |
| dihydroergotamine | Severe acute respiratory syndrome-related coronavirus | Ki | 107.3600 | 1 | 1 |
| abietic acid | Severe acute respiratory syndrome-related coronavirus | IC50 | 189.1000 | 2 | 2 |
| 4-(dimethylamino)benzoic acid | Severe acute respiratory syndrome-related coronavirus | Ki | 1.3800 | 1 | 1 |
| agaric acid | Severe acute respiratory syndrome-related coronavirus | IC50 | 23.5400 | 1 | 1 |
| phenethyl isothiocyanate | Severe acute respiratory syndrome-related coronavirus | IC50 | 10.1300 | 1 | 1 |
| 1,2-benzisothiazoline-3-one | Severe acute respiratory syndrome-related coronavirus | IC50 | 0.6600 | 1 | 1 |
| pyrithione zinc | Severe acute respiratory syndrome-related coronavirus | Ki | 0.1700 | 1 | 1 |
| zinc ethylphenyldithiocarbamate | Severe acute respiratory syndrome-related coronavirus | Ki | 1.0000 | 2 | 2 |
| nelfinavir | Severe acute respiratory syndrome-related coronavirus | IC50 | 41.5000 | 1 | 1 |
| baicalin | Severe acute respiratory syndrome-related coronavirus | IC50 | 6.4100 | 1 | 1 |
| 1,2,3,4,6-pentakis-O-galloyl-beta-D-glucose | Severe acute respiratory syndrome-related coronavirus | IC50 | 27.7700 | 1 | 1 |
| sinefungin | Severe acute respiratory syndrome-related coronavirus | IC50 | 0.3190 | 1 | 2 |
| vanitiolide | Severe acute respiratory syndrome-related coronavirus | IC50 | 4.6000 | 1 | 1 |
| hesperetin | Severe acute respiratory syndrome-related coronavirus | IC50 | 34.1500 | 2 | 2 |
| LSM-4272 | Severe acute respiratory syndrome-related coronavirus | IC50 | 9.9600 | 1 | 1 |
| calpeptin | Severe acute respiratory syndrome-related coronavirus | IC50 | 8.5000 | 2 | 3 |
| lopinavir | Severe acute respiratory syndrome-related coronavirus | Ki | 15.0000 | 1 | 1 |
| zpck | Severe acute respiratory syndrome-related coronavirus | Ki | 0.3100 | 1 | 1 |
| tingenone | Severe acute respiratory syndrome-related coronavirus | IC50 | 9.9000 | 2 | 2 |
| tingenone | Severe acute respiratory syndrome-related coronavirus | Ki | 4.0000 | 2 | 2 |
| alexidine dihydrchloride | Severe acute respiratory syndrome-related coronavirus | IC50 | 22.4667 | 3 | 3 |
| tanshinone | Severe acute respiratory syndrome-related coronavirus | IC50 | 38.7000 | 1 | 1 |
| tanshinone | Severe acute respiratory syndrome-related coronavirus | Ki | 13.7000 | 1 | 1 |
| celastrol | Severe acute respiratory syndrome-related coronavirus | IC50 | 10.3000 | 2 | 2 |
| celastrol | Severe acute respiratory syndrome-related coronavirus | Ki | 4.2000 | 2 | 2 |
| phlorofucofuroeckol a | Severe acute respiratory syndrome-related coronavirus | IC50 | 95.6500 | 2 | 2 |
| phlorofucofuroeckol a | Severe acute respiratory syndrome-related coronavirus | Ki | 10.6000 | 1 | 1 |
| eckol | Severe acute respiratory syndrome-related coronavirus | IC50 | 8.8000 | 1 | 1 |
| eckol | Severe acute respiratory syndrome-related coronavirus | Ki | 8.2000 | 1 | 1 |
| moxifloxacin | Severe acute respiratory syndrome-related coronavirus | Ki | 249.0000 | 1 | 1 |
| celastrol methyl ester | Severe acute respiratory syndrome-related coronavirus | IC50 | 5.5000 | 2 | 2 |
| celastrol methyl ester | Severe acute respiratory syndrome-related coronavirus | Ki | 3.1000 | 2 | 2 |
| miltirone | Severe acute respiratory syndrome-related coronavirus | IC50 | 21.1000 | 1 | 1 |
| cryptotanshinone | Severe acute respiratory syndrome-related coronavirus | IC50 | 226.7000 | 1 | 1 |
| cryptotanshinone | Severe acute respiratory syndrome-related coronavirus | Ki | 9.0000 | 1 | 1 |
| tanshinone ii a | Severe acute respiratory syndrome-related coronavirus | IC50 | 44.9500 | 2 | 2 |
| 2-phenyl-1,2-benzisothiazol-3-(2h)-one | Severe acute respiratory syndrome-related coronavirus | IC50 | 0.4900 | 1 | 1 |
| carboxyebselen | Severe acute respiratory syndrome-related coronavirus | IC50 | 0.1300 | 1 | 1 |
| darunavir | Severe acute respiratory syndrome-related coronavirus | Ki | 518.0000 | 1 | 1 |
| 1-methylpropyl-2-imidazolyl disulfide | Severe acute respiratory syndrome-related coronavirus | IC50 | 21.1300 | 2 | 3 |
| nsc 95397 | Severe acute respiratory syndrome-related coronavirus | IC50 | 17.9300 | 1 | 1 |
| nsc 663284 | Severe acute respiratory syndrome-related coronavirus | IC50 | 2.6300 | 1 | 1 |
| abacavir | Severe acute respiratory syndrome-related coronavirus | IC50 | 18.6250 | 1 | 2 |
| ferruginol | Severe acute respiratory syndrome-related coronavirus | IC50 | 49.6000 | 2 | 3 |
| isopimaric acid | Severe acute respiratory syndrome-related coronavirus | IC50 | 283.5000 | 2 | 3 |
| acetylleucyl-leucyl-norleucinal | Severe acute respiratory syndrome-related coronavirus | IC50 | 8.6000 | 1 | 1 |
| gw 3965 | Severe acute respiratory syndrome-related coronavirus | IC50 | 21.5200 | 1 | 1 |
| benzyloxycarbonylleucyl-leucyl-leucine aldehyde | Severe acute respiratory syndrome-related coronavirus | IC50 | 6.9500 | 3 | 4 |
| tenofovir | Severe acute respiratory syndrome-related coronavirus | IC50 | 12.9850 | 1 | 2 |
| 1-(2-Naphthylmethyl)-2,3-dioxo-indoline-5-carboxamide | Severe acute respiratory syndrome-related coronavirus | IC50 | 0.2617 | 2 | 3 |
| 1-(2-Naphthylmethyl)-2,3-dioxo-indoline-5-carboxamide | Severe acute respiratory syndrome-related coronavirus | Ki | 0.1200 | 1 | 1 |
| hirsutanone | Severe acute respiratory syndrome-related coronavirus | IC50 | 4.1000 | 1 | 1 |
| 1-(4-Methoxyphenyl)-2-nitroethylene | Severe acute respiratory syndrome-related coronavirus | IC50 | 47.5000 | 1 | 1 |
| curcumin | Severe acute respiratory syndrome-related coronavirus | IC50 | 31.7500 | 1 | 2 |
| chlorogenic acid | Severe acute respiratory syndrome-related coronavirus | IC50 | 39.4800 | 1 | 1 |
| CID 2131972 | Severe acute respiratory syndrome-related coronavirus | IC50 | 38.5700 | 1 | 1 |
| CID 2131972 | Severe acute respiratory syndrome-related coronavirus | Ki | 9.1100 | 2 | 2 |
| 5-(4-Chloro-benzenesulfonyl)-pyrimidine-2,4-diamine | Severe acute respiratory syndrome-related coronavirus | IC50 | 6.0000 | 3 | 3 |
| S-[5-(trifluoromethyl)-4H-1,2,4-triazol-3-yl] 5-(phenylethynyl)furan-2-carbothioate | Severe acute respiratory syndrome-related coronavirus | IC50 | 3.0000 | 4 | 4 |
| dieckol | Severe acute respiratory syndrome-related coronavirus | IC50 | 35.4000 | 2 | 2 |
| dieckol | Severe acute respiratory syndrome-related coronavirus | Ki | 2.4000 | 1 | 1 |
| telaprevir | Severe acute respiratory syndrome-related coronavirus | IC50 | 12.2400 | 3 | 3 |
| N-(4-Butan-2-ylphenyl)-N-[2-(cyclopentylamino)-2-oxo-1-pyridin-3-ylethyl]furan-2-carboxamide | Severe acute respiratory syndrome-related coronavirus | IC50 | 14.9200 | 3 | 5 |
| 8-(Trifluoromethyl)-9H-purin-6-amine | Severe acute respiratory syndrome-related coronavirus | IC50 | 37.7571 | 6 | 7 |
| 8-(Trifluoromethyl)-9H-purin-6-amine | Severe acute respiratory syndrome-related coronavirus | Ki | 10.3250 | 3 | 4 |
| l 663536 | Severe acute respiratory syndrome-related coronavirus | IC50 | 21.5200 | 1 | 1 |
| suramin sodium | Severe acute respiratory syndrome-related coronavirus | IC50 | 6.5000 | 1 | 1 |
| 4-benzyl-2-methyl-1,2,4-thiadiazolidine-3,5-dione | Severe acute respiratory syndrome-related coronavirus | IC50 | 2.1500 | 1 | 1 |
| sitagliptin | Severe acute respiratory syndrome-related coronavirus | IC50 | 16.1400 | 1 | 1 |
| N-Cyclopentyl-2-(N-methyl3-chlorobenzenesulfonamido)acetamide | Severe acute respiratory syndrome-related coronavirus | IC50 | 100.4700 | 2 | 2 |
| ginkgetin | Severe acute respiratory syndrome-related coronavirus | IC50 | 32.2333 | 3 | 3 |
| ginkgetin | Severe acute respiratory syndrome-related coronavirus | Ki | 30.2000 | 2 | 2 |
| quercetin | Severe acute respiratory syndrome-related coronavirus | IC50 | 26.4250 | 4 | 4 |
| quercetin | Severe acute respiratory syndrome-related coronavirus | Ki | 7.4000 | 1 | 1 |
| apigenin | Severe acute respiratory syndrome-related coronavirus | IC50 | 280.5333 | 3 | 3 |
| luteolin | Severe acute respiratory syndrome-related coronavirus | IC50 | 20.0000 | 2 | 2 |
| amentoflavone | Severe acute respiratory syndrome-related coronavirus | IC50 | 8.3000 | 3 | 3 |
| amentoflavone | Severe acute respiratory syndrome-related coronavirus | Ki | 13.8000 | 2 | 2 |
| baicalein | Severe acute respiratory syndrome-related coronavirus | IC50 | 0.9400 | 1 | 1 |
| hyperoside | Severe acute respiratory syndrome-related coronavirus | IC50 | 46.6000 | 2 | 2 |
| sciadopitysin | Severe acute respiratory syndrome-related coronavirus | IC50 | 38.4000 | 3 | 3 |
| sciadopitysin | Severe acute respiratory syndrome-related coronavirus | Ki | 35.6000 | 2 | 2 |
| scutellarein | Severe acute respiratory syndrome-related coronavirus | IC50 | 3.0200 | 1 | 1 |
| daidzein | Severe acute respiratory syndrome-related coronavirus | IC50 | 105.0000 | 1 | 1 |
| savinin | Severe acute respiratory syndrome-related coronavirus | IC50 | 25.0000 | 1 | 1 |
| benzyloxycarbonyl-phe-ala-fluormethylketone | Severe acute respiratory syndrome-related coronavirus | Ki | 64.0000 | 1 | 1 |
| bilobetin | Severe acute respiratory syndrome-related coronavirus | IC50 | 72.3000 | 2 | 2 |
| bilobetin | Severe acute respiratory syndrome-related coronavirus | Ki | 80.4000 | 1 | 1 |
| indinavir sulfate | Severe acute respiratory syndrome-related coronavirus | IC50 | 22.5300 | 1 | 2 |
| cinanserin | Severe acute respiratory syndrome-related coronavirus | IC50 | 5.0000 | 1 | 1 |
| N-[(5-methyl-1,2-oxazol-3-yl)carbonyl]-L-alanyl-L-valyl-N-{(2S,3E)-5-(benzyloxy)-5-oxo-1-[(3S)-2-oxopyrrolidin-3-yl]pent-3-en-2-yl}-L-leucinamide | Severe acute respiratory syndrome-related coronavirus | IC50 | 9.0000 | 1 | 1 |
| N-[(5-methyl-1,2-oxazol-3-yl)carbonyl]-L-alanyl-L-valyl-N-{(2S,3E)-5-(benzyloxy)-5-oxo-1-[(3S)-2-oxopyrrolidin-3-yl]pent-3-en-2-yl}-L-leucinamide | Severe acute respiratory syndrome-related coronavirus | Ki | 5.4500 | 1 | 2 |
| broussochalcone a | Severe acute respiratory syndrome-related coronavirus | IC50 | 25.6500 | 1 | 2 |
| rupintrivir | Severe acute respiratory syndrome-related coronavirus | IC50 | 235.0000 | 3 | 4 |
| rupintrivir | Severe acute respiratory syndrome-related coronavirus | Ki | 10.0000 | 1 | 2 |
| Ethyl (E,4S)-4-[[(2S)-2-[[(2S)-3-methyl-2-(phenylmethoxycarbonylamino)butanoyl]amino]-3-phenylpropanoyl]amino]-5-[(3S)-2-oxopyrrolidin-3-yl]pent-2-enoate | Severe acute respiratory syndrome-related coronavirus | IC50 | 85.0000 | 1 | 1 |
| Ethyl (E,4S)-4-[[(2S)-2-[[(2S)-3-methyl-2-(phenylmethoxycarbonylamino)butanoyl]amino]-3-phenylpropanoyl]amino]-5-[(3S)-2-oxopyrrolidin-3-yl]pent-2-enoate | Severe acute respiratory syndrome-related coronavirus | Ki | 2.2600 | 3 | 3 |
| mdl 201053 | Severe acute respiratory syndrome-related coronavirus | Ki | 25.7000 | 1 | 1 |
| 5-Chloro-3-pyridinyl 2-furoate | Severe acute respiratory syndrome-related coronavirus | IC50 | 0.0600 | 3 | 3 |
| carbobenzoxy-leucyl-leucyl-norvalinal | Severe acute respiratory syndrome-related coronavirus | IC50 | 6.5700 | 2 | 2 |
| sp 100030 | Severe acute respiratory syndrome-related coronavirus | IC50 | 28.8500 | 1 | 1 |
| gw0742 | Severe acute respiratory syndrome-related coronavirus | IC50 | 22.2700 | 1 | 1 |
| benzyloxycarbonyl-isoleucyl-glutamyl(o-tert-butyl)-alanyl-leucinal | Severe acute respiratory syndrome-related coronavirus | IC50 | 10.3800 | 1 | 1 |
| sepantronium | Severe acute respiratory syndrome-related coronavirus | IC50 | 13.6000 | 1 | 1 |
| n-(3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl)-3-(2-((((1,1-dimethylethyl)amino)carbonyl)amino)-3,3-dimethyl-1-oxobutyl)-6,6-dimethyl-3-azabicyclo(3.1.0)hexan-2-carboxamide | Severe acute respiratory syndrome-related coronavirus | IC50 | 5.9150 | 3 | 4 |
| triptohypol C | Severe acute respiratory syndrome-related coronavirus | IC50 | 21.7000 | 2 | 2 |
| eckstolonol | Severe acute respiratory syndrome-related coronavirus | IC50 | 152.4000 | 2 | 2 |
| 7-phloroeckol | Severe acute respiratory syndrome-related coronavirus | IC50 | 77.0500 | 2 | 2 |
| 7-phloroeckol | Severe acute respiratory syndrome-related coronavirus | Ki | 19.3000 | 1 | 1 |
| 2-(4-chlorophenyl)-1,2-benzothiazol-3-one | Severe acute respiratory syndrome-related coronavirus | IC50 | 0.3900 | 1 | 1 |
| np 031112 | Severe acute respiratory syndrome-related coronavirus | IC50 | 1.5500 | 2 | 2 |
| Dihydrotanshinone I | Severe acute respiratory syndrome-related coronavirus | IC50 | 14.4000 | 1 | 1 |
| Dihydrotanshinone I | Severe acute respiratory syndrome-related coronavirus | Ki | 11.2000 | 1 | 1 |
| PF-00835231 | Severe acute respiratory syndrome-related coronavirus | IC50 | 0.0053 | 3 | 3 |
| mk-0893 | Severe acute respiratory syndrome-related coronavirus | IC50 | 24.3300 | 1 | 1 |
| Benzotriazol-1-yl 1H-indole-5-carboxylate | Severe acute respiratory syndrome-related coronavirus | Ki | 0.0075 | 3 | 3 |
| tannins | Severe acute respiratory syndrome-related coronavirus | IC50 | 2.1000 | 1 | 1 |
| tannins | Severe acute respiratory syndrome-related coronavirus | Ki | 1.4000 | 1 | 1 |
| oritavancin | Severe acute respiratory syndrome-related coronavirus | IC50 | 24.1500 | 1 | 1 |
| 5-Bromopyridin-3-yl furan-2-carboxylate | Severe acute respiratory syndrome-related coronavirus | IC50 | 0.0500 | 2 | 2 |
| 5-Chloropyridin-3-yl 5-(4-chlorophenyl)furan-2-carboxylate | Severe acute respiratory syndrome-related coronavirus | IC50 | 0.0630 | 2 | 2 |
| (5-Chloropyridin-3-yl) 1H-indole-5-carboxylate | Severe acute respiratory syndrome-related coronavirus | IC50 | 0.8500 | 3 | 3 |
| 5-Chloropyridin-3-yl 1H-indole-2-carboxylate | Severe acute respiratory syndrome-related coronavirus | IC50 | 0.0550 | 3 | 4 |
| phenylmercuric acetate | Severe acute respiratory syndrome-related coronavirus | IC50 | 0.4000 | 1 | 1 |
| phenylmercuric acetate | Severe acute respiratory syndrome-related coronavirus | Ki | 0.5033 | 2 | 3 |
| thimerosal | Severe acute respiratory syndrome-related coronavirus | Ki | 2.4000 | 1 | 1 |
| GRL-0617 | Severe acute respiratory syndrome-related coronavirus | IC50 | 1.1567 | 3 | 3 |
| (5-Chloropyridin-3-yl) 1H-indole-4-carboxylate | Severe acute respiratory syndrome-related coronavirus | IC50 | 0.1008 | 3 | 4 |
| KOM70144 | Severe acute respiratory syndrome-related coronavirus | IC50 | 0.5600 | 2 | 2 |
| Benzyl N-[(2S)-3-methyl-1-[[(2S)-4-methyl-1-oxo-1-[[(2S)-1-oxo-3-[(3S)-2-oxopyrrolidin-3-yl]-1-(1,3-thiazol-2-yl)propan-2-yl]amino]pentan-2-yl]amino]-1-oxobutan-2-yl]carbamate | Severe acute respiratory syndrome-related coronavirus | Ki | 2.2000 | 3 | 3 |
| amg-837 | Severe acute respiratory syndrome-related coronavirus | IC50 | 24.1500 | 1 | 1 |
| N-[(1R)-2-(tert-butylamino)-2-oxo-1-(3-pyridinyl)ethyl]-N-(4-tert-butylphenyl)-2-furancarboxamide | Severe acute respiratory syndrome-related coronavirus | IC50 | 2.3250 | 3 | 4 |
| bictegravir | Severe acute respiratory syndrome-related coronavirus | Ki | 302.0000 | 1 | 1 |
| sildenafil | Severe acute respiratory syndrome-related coronavirus | IC50 | 10.3535 | 1 | 2 |
| amg531 | Severe acute respiratory syndrome-related coronavirus | IC50 | 21.5200 | 1 | 1 |
| N-[(2S)-3-cyclohexyl-1-oxo-1-({(2S)-1-oxo-3-[(3S)-2-oxopyrrolidin-3-yl]propan-2-yl}amino)propan-2-yl]-1H-indole-2-carboxamide | Severe acute respiratory syndrome-related coronavirus | IC50 | 0.0402 | 4 | 5 |
| 3-fluoro-Nalpha-(1H-indol-2-ylcarbonyl)-N-{(2S)-1-oxo-3-[(3S)-2-oxopyrrolidin-3-yl]propan-2-yl}-L-phenylalaninamide | Severe acute respiratory syndrome-related coronavirus | IC50 | 0.0358 | 4 | 4 |
Drugs with Activation Measurements
Perspectives on SARS-CoV-2 Main Protease Inhibitors.Journal of medicinal chemistry, , 12-09, Volume: 64, Issue:23, 2021
The recent outbreaks of human coronaviruses: A medicinal chemistry perspective.Medicinal research reviews, , Volume: 41, Issue:1, 2021
An Overview of Severe Acute Respiratory Syndrome-Coronavirus (SARS-CoV) 3CL Protease Inhibitors: Peptidomimetics and Small Molecule Chemotherapy.Journal of medicinal chemistry, , 07-28, Volume: 59, Issue:14, 2016
Quantitative high-throughput screening identifies inhibitors of anthrax-induced cell death.Bioorganic & medicinal chemistry, , Jul-15, Volume: 17, Issue:14, 2009
Discovery of potent anilide inhibitors against the severe acute respiratory syndrome 3CL protease.Journal of medicinal chemistry, , Jun-30, Volume: 48, Issue:13, 2005
Perspectives on SARS-CoV-2 Main Protease Inhibitors.Journal of medicinal chemistry, , 12-09, Volume: 64, Issue:23, 2021
Biflavonoids from Torreya nucifera displaying SARS-CoV 3CL(pro) inhibition.Bioorganic & medicinal chemistry, , Nov-15, Volume: 18, Issue:22, 2010
Perspectives on SARS-CoV-2 Main Protease Inhibitors.Journal of medicinal chemistry, , 12-09, Volume: 64, Issue:23, 2021
An Overview of Severe Acute Respiratory Syndrome-Coronavirus (SARS-CoV) 3CL Protease Inhibitors: Peptidomimetics and Small Molecule Chemotherapy.Journal of medicinal chemistry, , 07-28, Volume: 59, Issue:14, 2016
Perspectives on SARS-CoV-2 Main Protease Inhibitors.Journal of medicinal chemistry, , 12-09, Volume: 64, Issue:23, 2021
SARS-CoV 3CLpro inhibitory effects of quinone-methide triterpenes from Tripterygium regelii.Bioorganic & medicinal chemistry letters, , Mar-15, Volume: 20, Issue:6, 2010
Perspectives on SARS-CoV-2 Main Protease Inhibitors.Journal of medicinal chemistry, , 12-09, Volume: 64, Issue:23, 2021
SARS-CoV 3CLpro inhibitory effects of quinone-methide triterpenes from Tripterygium regelii.Bioorganic & medicinal chemistry letters, , Mar-15, Volume: 20, Issue:6, 2010
Perspectives on SARS-CoV-2 Main Protease Inhibitors.Journal of medicinal chemistry, , 12-09, Volume: 64, Issue:23, 2021
SARS-CoV 3CLpro inhibitory effects of quinone-methide triterpenes from Tripterygium regelii.Bioorganic & medicinal chemistry letters, , Mar-15, Volume: 20, Issue:6, 2010
Perspectives on SARS-CoV-2 Main Protease Inhibitors.Journal of medicinal chemistry, , 12-09, Volume: 64, Issue:23, 2021
Biflavonoids from Torreya nucifera displaying SARS-CoV 3CL(pro) inhibition.Bioorganic & medicinal chemistry, , Nov-15, Volume: 18, Issue:22, 2010
Perspectives on SARS-CoV-2 Main Protease Inhibitors.Journal of medicinal chemistry, , 12-09, Volume: 64, Issue:23, 2021
Biflavonoids from Torreya nucifera displaying SARS-CoV 3CL(pro) inhibition.Bioorganic & medicinal chemistry, , Nov-15, Volume: 18, Issue:22, 2010
An Overview of Severe Acute Respiratory Syndrome-Coronavirus (SARS-CoV) 3CL Protease Inhibitors: Peptidomimetics and Small Molecule Chemotherapy.Journal of medicinal chemistry, , 07-28, Volume: 59, Issue:14, 2016
Virtual screening identification of novel severe acute respiratory syndrome 3C-like protease inhibitors and in vitro confirmation.Bioorganic & medicinal chemistry letters, , May-15, Volume: 21, Issue:10, 2011
A Patent Review on SARS Coronavirus Main Protease (3CLChemMedChem, , 01-05, Volume: 17, Issue:1, 2022
Perspectives on SARS-CoV-2 Main Protease Inhibitors.Journal of medicinal chemistry, , 12-09, Volume: 64, Issue:23, 2021
Structure-based drug design and structural biology study of novel nonpeptide inhibitors of severe acute respiratory syndrome coronavirus main protease.Journal of medicinal chemistry, , Aug-24, Volume: 49, Issue:17, 2006
Perspectives on SARS-CoV-2 Main Protease Inhibitors.Journal of medicinal chemistry, , 12-09, Volume: 64, Issue:23, 2021
The recent outbreaks of human coronaviruses: A medicinal chemistry perspective.Medicinal research reviews, , Volume: 41, Issue:1, 2021
An Overview of Severe Acute Respiratory Syndrome-Coronavirus (SARS-CoV) 3CL Protease Inhibitors: Peptidomimetics and Small Molecule Chemotherapy.Journal of medicinal chemistry, , 07-28, Volume: 59, Issue:14, 2016
Structure-based drug design and structural biology study of novel nonpeptide inhibitors of severe acute respiratory syndrome coronavirus main protease.Journal of medicinal chemistry, , Aug-24, Volume: 49, Issue:17, 2006
Perspectives on SARS-CoV-2 Main Protease Inhibitors.Journal of medicinal chemistry, , 12-09, Volume: 64, Issue:23, 2021
The recent outbreaks of human coronaviruses: A medicinal chemistry perspective.Medicinal research reviews, , Volume: 41, Issue:1, 2021
An Overview of Severe Acute Respiratory Syndrome-Coronavirus (SARS-CoV) 3CL Protease Inhibitors: Peptidomimetics and Small Molecule Chemotherapy.Journal of medicinal chemistry, , 07-28, Volume: 59, Issue:14, 2016
Perspectives on SARS-CoV-2 Main Protease Inhibitors.Journal of medicinal chemistry, , 12-09, Volume: 64, Issue:23, 2021
An Overview of Severe Acute Respiratory Syndrome-Coronavirus (SARS-CoV) 3CL Protease Inhibitors: Peptidomimetics and Small Molecule Chemotherapy.Journal of medicinal chemistry, , 07-28, Volume: 59, Issue:14, 2016
Inhibitor recognition specificity of MERS-CoV papain-like protease may differ from that of SARS-CoV.ACS chemical biology, , Jun-19, Volume: 10, Issue:6, 2015
Identification of novel drug scaffolds for inhibition of SARS-CoV 3-Chymotrypsin-like protease using virtual and high-throughput screenings.Bioorganic & medicinal chemistry, , Jan-01, Volume: 22, Issue:1, 2014
Perspectives on SARS-CoV-2 Main Protease Inhibitors.Journal of medicinal chemistry, , 12-09, Volume: 64, Issue:23, 2021
An Overview of Severe Acute Respiratory Syndrome-Coronavirus (SARS-CoV) 3CL Protease Inhibitors: Peptidomimetics and Small Molecule Chemotherapy.Journal of medicinal chemistry, , 07-28, Volume: 59, Issue:14, 2016
Biflavonoids from Torreya nucifera displaying SARS-CoV 3CL(pro) inhibition.Bioorganic & medicinal chemistry, , Nov-15, Volume: 18, Issue:22, 2010
Perspectives on SARS-CoV-2 Main Protease Inhibitors.Journal of medicinal chemistry, , 12-09, Volume: 64, Issue:23, 2021
The recent outbreaks of human coronaviruses: A medicinal chemistry perspective.Medicinal research reviews, , Volume: 41, Issue:1, 2021
An Overview of Severe Acute Respiratory Syndrome-Coronavirus (SARS-CoV) 3CL Protease Inhibitors: Peptidomimetics and Small Molecule Chemotherapy.Journal of medicinal chemistry, , 07-28, Volume: 59, Issue:14, 2016
Biflavonoids from Torreya nucifera displaying SARS-CoV 3CL(pro) inhibition.Bioorganic & medicinal chemistry, , Nov-15, Volume: 18, Issue:22, 2010
Investigation of the pharmacophore space of Severe Acute Respiratory Syndrome coronavirus (SARS-CoV) NTPase/helicase by dihydroxychromone derivatives.Bioorganic & medicinal chemistry letters, , Aug-15, Volume: 19, Issue:16, 2009
Perspectives on SARS-CoV-2 Main Protease Inhibitors.Journal of medicinal chemistry, , 12-09, Volume: 64, Issue:23, 2021
An Overview of Severe Acute Respiratory Syndrome-Coronavirus (SARS-CoV) 3CL Protease Inhibitors: Peptidomimetics and Small Molecule Chemotherapy.Journal of medicinal chemistry, , 07-28, Volume: 59, Issue:14, 2016
Biflavonoids from Torreya nucifera displaying SARS-CoV 3CL(pro) inhibition.Bioorganic & medicinal chemistry, , Nov-15, Volume: 18, Issue:22, 2010
Perspectives on SARS-CoV-2 Main Protease Inhibitors.Journal of medicinal chemistry, , 12-09, Volume: 64, Issue:23, 2021
The recent outbreaks of human coronaviruses: A medicinal chemistry perspective.Medicinal research reviews, , Volume: 41, Issue:1, 2021
An Overview of Severe Acute Respiratory Syndrome-Coronavirus (SARS-CoV) 3CL Protease Inhibitors: Peptidomimetics and Small Molecule Chemotherapy.Journal of medicinal chemistry, , 07-28, Volume: 59, Issue:14, 2016
Biflavonoids from Torreya nucifera displaying SARS-CoV 3CL(pro) inhibition.Bioorganic & medicinal chemistry, , Nov-15, Volume: 18, Issue:22, 2010
Perspectives on SARS-CoV-2 Main Protease Inhibitors.Journal of medicinal chemistry, , 12-09, Volume: 64, Issue:23, 2021
The recent outbreaks of human coronaviruses: A medicinal chemistry perspective.Medicinal research reviews, , Volume: 41, Issue:1, 2021
Biflavonoids from Torreya nucifera displaying SARS-CoV 3CL(pro) inhibition.Bioorganic & medicinal chemistry, , Nov-15, Volume: 18, Issue:22, 2010
A Patent Review on SARS Coronavirus Main Protease (3CLChemMedChem, , 01-05, Volume: 17, Issue:1, 2022
An Overview of Severe Acute Respiratory Syndrome-Coronavirus (SARS-CoV) 3CL Protease Inhibitors: Peptidomimetics and Small Molecule Chemotherapy.Journal of medicinal chemistry, , 07-28, Volume: 59, Issue:14, 2016
Perspectives on SARS-CoV-2 Main Protease Inhibitors.Journal of medicinal chemistry, , 12-09, Volume: 64, Issue:23, 2021
An Overview of Severe Acute Respiratory Syndrome-Coronavirus (SARS-CoV) 3CL Protease Inhibitors: Peptidomimetics and Small Molecule Chemotherapy.Journal of medicinal chemistry, , 07-28, Volume: 59, Issue:14, 2016
Biflavonoids from Torreya nucifera displaying SARS-CoV 3CL(pro) inhibition.Bioorganic & medicinal chemistry, , Nov-15, Volume: 18, Issue:22, 2010
Perspectives on SARS-CoV-2 Main Protease Inhibitors.Journal of medicinal chemistry, , 12-09, Volume: 64, Issue:23, 2021
Biflavonoids from Torreya nucifera displaying SARS-CoV 3CL(pro) inhibition.Bioorganic & medicinal chemistry, , Nov-15, Volume: 18, Issue:22, 2010
A Patent Review on SARS Coronavirus Main Protease (3CLChemMedChem, , 01-05, Volume: 17, Issue:1, 2022
Perspectives on SARS-CoV-2 Main Protease Inhibitors.Journal of medicinal chemistry, , 12-09, Volume: 64, Issue:23, 2021
A Patent Review on SARS Coronavirus Main Protease (3CLChemMedChem, , 01-05, Volume: 17, Issue:1, 2022
The recent outbreaks of human coronaviruses: A medicinal chemistry perspective.Medicinal research reviews, , Volume: 41, Issue:1, 2021
Inhibition of the severe acute respiratory syndrome 3CL protease by peptidomimetic alpha,beta-unsaturated esters.Bioorganic & medicinal chemistry, , Sep-01, Volume: 13, Issue:17, 2005
A Patent Review on SARS Coronavirus Main Protease (3CLChemMedChem, , 01-05, Volume: 17, Issue:1, 2022
Perspectives on SARS-CoV-2 Main Protease Inhibitors.Journal of medicinal chemistry, , 12-09, Volume: 64, Issue:23, 2021
Synthesis, crystal structure, structure-activity relationships, and antiviral activity of a potent SARS coronavirus 3CL protease inhibitor.Journal of medicinal chemistry, , Aug-10, Volume: 49, Issue:16, 2006
Inhibition of the severe acute respiratory syndrome 3CL protease by peptidomimetic alpha,beta-unsaturated esters.Bioorganic & medicinal chemistry, , Sep-01, Volume: 13, Issue:17, 2005
Perspectives on SARS-CoV-2 Main Protease Inhibitors.Journal of medicinal chemistry, , 12-09, Volume: 64, Issue:23, 2021
The recent outbreaks of human coronaviruses: A medicinal chemistry perspective.Medicinal research reviews, , Volume: 41, Issue:1, 2021
An Overview of Severe Acute Respiratory Syndrome-Coronavirus (SARS-CoV) 3CL Protease Inhibitors: Peptidomimetics and Small Molecule Chemotherapy.Journal of medicinal chemistry, , 07-28, Volume: 59, Issue:14, 2016
Perspectives on SARS-CoV-2 Main Protease Inhibitors.Journal of medicinal chemistry, , 12-09, Volume: 64, Issue:23, 2021
SARS-CoV 3CLpro inhibitory effects of quinone-methide triterpenes from Tripterygium regelii.Bioorganic & medicinal chemistry letters, , Mar-15, Volume: 20, Issue:6, 2010
Perspectives on SARS-CoV-2 Main Protease Inhibitors.Journal of medicinal chemistry, , 12-09, Volume: 64, Issue:23, 2021
The recent outbreaks of human coronaviruses: A medicinal chemistry perspective.Medicinal research reviews, , Volume: 41, Issue:1, 2021
Stable benzotriazole esters as mechanism-based inactivators of the severe acute respiratory syndrome 3CL protease.Chemistry & biology, , Volume: 13, Issue:3, 2006
Perspectives on SARS-CoV-2 Main Protease Inhibitors.Journal of medicinal chemistry, , 12-09, Volume: 64, Issue:23, 2021
An Overview of Severe Acute Respiratory Syndrome-Coronavirus (SARS-CoV) 3CL Protease Inhibitors: Peptidomimetics and Small Molecule Chemotherapy.Journal of medicinal chemistry, , 07-28, Volume: 59, Issue:14, 2016
Perspectives on SARS-CoV-2 Main Protease Inhibitors.Journal of medicinal chemistry, , 12-09, Volume: 64, Issue:23, 2021
The recent outbreaks of human coronaviruses: A medicinal chemistry perspective.Medicinal research reviews, , Volume: 41, Issue:1, 2021
An Overview of Severe Acute Respiratory Syndrome-Coronavirus (SARS-CoV) 3CL Protease Inhibitors: Peptidomimetics and Small Molecule Chemotherapy.Journal of medicinal chemistry, , 07-28, Volume: 59, Issue:14, 2016
Perspectives on SARS-CoV-2 Main Protease Inhibitors.Journal of medicinal chemistry, , 12-09, Volume: 64, Issue:23, 2021
The recent outbreaks of human coronaviruses: A medicinal chemistry perspective.Medicinal research reviews, , Volume: 41, Issue:1, 2021
An Overview of Severe Acute Respiratory Syndrome-Coronavirus (SARS-CoV) 3CL Protease Inhibitors: Peptidomimetics and Small Molecule Chemotherapy.Journal of medicinal chemistry, , 07-28, Volume: 59, Issue:14, 2016
Perspectives on SARS-CoV-2 Main Protease Inhibitors.Journal of medicinal chemistry, , 12-09, Volume: 64, Issue:23, 2021
An Overview of Severe Acute Respiratory Syndrome-Coronavirus (SARS-CoV) 3CL Protease Inhibitors: Peptidomimetics and Small Molecule Chemotherapy.Journal of medicinal chemistry, , 07-28, Volume: 59, Issue:14, 2016
The recent outbreaks of human coronaviruses: A medicinal chemistry perspective.Medicinal research reviews, , Volume: 41, Issue:1, 2021
Inhibitor recognition specificity of MERS-CoV papain-like protease may differ from that of SARS-CoV.ACS chemical biology, , Jun-19, Volume: 10, Issue:6, 2015
Structure-based design, synthesis, and biological evaluation of a series of novel and reversible inhibitors for the severe acute respiratory syndrome-coronavirus papain-like protease.Journal of medicinal chemistry, , Aug-27, Volume: 52, Issue:16, 2009
Perspectives on SARS-CoV-2 Main Protease Inhibitors.Journal of medicinal chemistry, , 12-09, Volume: 64, Issue:23, 2021
The recent outbreaks of human coronaviruses: A medicinal chemistry perspective.Medicinal research reviews, , Volume: 41, Issue:1, 2021
An Overview of Severe Acute Respiratory Syndrome-Coronavirus (SARS-CoV) 3CL Protease Inhibitors: Peptidomimetics and Small Molecule Chemotherapy.Journal of medicinal chemistry, , 07-28, Volume: 59, Issue:14, 2016
The recent outbreaks of human coronaviruses: A medicinal chemistry perspective.Medicinal research reviews, , Volume: 41, Issue:1, 2021
Structure-based design, synthesis, and biological evaluation of a series of novel and reversible inhibitors for the severe acute respiratory syndrome-coronavirus papain-like protease.Journal of medicinal chemistry, , Aug-27, Volume: 52, Issue:16, 2009
Perspectives on SARS-CoV-2 Main Protease Inhibitors.Journal of medicinal chemistry, , 12-09, Volume: 64, Issue:23, 2021
An Overview of Severe Acute Respiratory Syndrome-Coronavirus (SARS-CoV) 3CL Protease Inhibitors: Peptidomimetics and Small Molecule Chemotherapy.Journal of medicinal chemistry, , 07-28, Volume: 59, Issue:14, 2016
New developments for the design, synthesis and biological evaluation of potent SARS-CoV 3CL(pro) inhibitors.Bioorganic & medicinal chemistry letters, , May-15, Volume: 19, Issue:10, 2009
Perspectives on SARS-CoV-2 Main Protease Inhibitors.Journal of medicinal chemistry, , 12-09, Volume: 64, Issue:23, 2021
The recent outbreaks of human coronaviruses: A medicinal chemistry perspective.Medicinal research reviews, , Volume: 41, Issue:1, 2021
An Overview of Severe Acute Respiratory Syndrome-Coronavirus (SARS-CoV) 3CL Protease Inhibitors: Peptidomimetics and Small Molecule Chemotherapy.Journal of medicinal chemistry, , 07-28, Volume: 59, Issue:14, 2016
Perspectives on SARS-CoV-2 Main Protease Inhibitors.Journal of medicinal chemistry, , 12-09, Volume: 64, Issue:23, 2021
A head-to-head comparison of the inhibitory activities of 15 peptidomimetic SARS-CoV-2 3CLpro inhibitors.Bioorganic & medicinal chemistry letters, , 09-15, Volume: 48, 2021
The recent outbreaks of human coronaviruses: A medicinal chemistry perspective.Medicinal research reviews, , Volume: 41, Issue:1, 2021
Perspectives on SARS-CoV-2 Main Protease Inhibitors.Journal of medicinal chemistry, , 12-09, Volume: 64, Issue:23, 2021
A head-to-head comparison of the inhibitory activities of 15 peptidomimetic SARS-CoV-2 3CLpro inhibitors.Bioorganic & medicinal chemistry letters, , 09-15, Volume: 48, 2021
The recent outbreaks of human coronaviruses: A medicinal chemistry perspective.Medicinal research reviews, , Volume: 41, Issue:1, 2021